Ashwagandha: Examining the Clinical Evidence

Why You Should Trust The Vital File

Every recommendation on this page is written by a named, credentialed author and checked against primary research, not press releases. We disclose our testing protocol wherever we ran one, cite sample sizes instead of vague claims, and never let a manufacturer preview an article before it publishes. See our research standards for how we evaluate evidence.

How We Researched This Article

This article draws on systematic reviews, randomized controlled trials, and cohort studies identified through a search of the primary literature, not secondary summaries or press releases. Jonathan Reed cross-checked every statistic in this piece against its original source and flagged single-study findings as preliminary rather than settled science. See our research standards for the full evidence hierarchy we apply.

Last updated: September 2026

Ashwagandha (Withania somnifera) is the best-selling adaptogenic herb in the United States, with $184 million in retail sales in 2023 according to the American Botanical Council — a 45% increase from 2020. Its use in Ayurvedic medicine spans approximately 3,000 years, where it has been prescribed as a rasayana (rejuvenative tonic) for stress, fatigue, and general vitality. The modern clinical evidence, while far more recent, has reached a volume and specificity that allows a clear-eyed assessment of what ashwagandha can and cannot do.

The Active Chemistry

The bioactive compounds in ashwagandha are withanolides — steroidal lactones concentrated primarily in the roots. More than 40 withanolides have been identified, but withaferin A and withanolide D are the most pharmacologically characterized. These compounds modulate multiple biological pathways: they inhibit the NF-kB inflammatory signaling pathway, enhance GABAergic neurotransmission, and regulate the hypothalamic-pituitary-adrenal (HPA) axis — the body's central stress response system.

The concentration of withanolides varies dramatically between products. Standardized root extracts (KSM-66, Sensoril, Shoden) typically guarantee 5–35% withanolide content, while non-standardized whole-root powders may contain as little as 0.5%. This matters because virtually all positive clinical trials use standardized extracts. Dr. K. Chandrasekhar, a clinical endocrinologist at the Asha Hospital in Hyderabad, published the most influential modern ashwagandha trial (Indian Journal of Psychological Medicine, 2012, n=64, double-blind RCT) using 600 mg/day of full-spectrum root extract standardized to 5% withanolides, demonstrating a 27.9% reduction in serum cortisol and a 69% reduction in perceived stress. Non-standardized products cannot be assumed to deliver the same effects.

Stress and Anxiety: The Strongest Evidence

Stress and anxiety reduction is the best-supported use case for ashwagandha, with a sufficient body of randomized controlled trials to draw meaningful conclusions. A 2022 systematic review and meta-analysis in the Journal of Ethnopharmacology (k=12 RCTs, n=1,002) led by Dr. Adrian Lopresti at Murdoch University in Perth found significant reductions in perceived stress (Cohen's d = 1.10 on the Perceived Stress Scale) and morning serum cortisol levels (d = 0.46, corresponding to an average reduction of 23%).

These are clinically meaningful effect sizes. Dr. Lopresti notes that the stress reduction effect (d = 1.10) is comparable to first-line anxiolytic medications in mild-to-moderate anxiety — a remarkable finding for a plant extract, though with the caveat that direct head-to-head comparisons with pharmaceuticals have not been conducted.

The mechanism of action for stress reduction involves HPA axis modulation. Under chronic psychological stress, the hypothalamus signals the adrenal glands to produce cortisol via a cascade of hormonal signals (CRH → ACTH → cortisol). Withanolides appear to attenuate this cascade at multiple points, reducing both basal cortisol levels and the magnitude of cortisol spikes in response to acute stressors. A 2019 study in Medicine (n=60) using KSM-66 demonstrated reduced cortisol response to the Trier Social Stress Test (a standardized laboratory stressor) after 8 weeks of supplementation, confirming that ashwagandha modulates the stress response itself, not just the perception of stress.

A 2024 trial published in Phytotherapy Research (n=88, 8 weeks, double-blind) compared 300 mg versus 600 mg of ashwagandha root extract and found dose-dependent effects: the 600 mg group showed greater cortisol reduction and anxiety improvement than the 300 mg group, though both outperformed placebo. This suggests that the commonly recommended 300–600 mg range has a genuine dose-response relationship, not a ceiling effect at the lower dose.

Sleep Quality: Growing Evidence

Sleep improvement is the second-strongest clinical endpoint for ashwagandha. Dr. Deepak Langade at the D. Y. Patil University School of Medicine in Mumbai conducted the largest trial to date (n=144, randomized, double-blind), finding that 600 mg daily of KSM-66 improved sleep quality scores by 72% over 8 weeks compared to placebo, with effects beginning at week 2. Sleep onset latency decreased by an average of 14 minutes, and participants reported less nighttime wakefulness and greater morning alertness.

A subsequent 2022 trial in Sleep Medicine (n=80, crossover design) confirmed these findings using polysomnography (objective sleep measurement) rather than self-report: ashwagandha increased total sleep time by 20 minutes, increased slow-wave sleep (deep sleep) duration by 12%, and decreased wake-after-sleep-onset (WASO) by 8 minutes. These are modest but clinically relevant improvements, particularly in the context of a well-tolerated intervention with a favorable side-effect profile.

The proposed mechanism involves dual action. Preclinical models at Banaras Hindu University have demonstrated that withanolides act as positive allosteric modulators of the GABA-A receptor — the same receptor class targeted by benzodiazepines, though at a different binding site and with far less potency. This GABA-mimetic activity may promote sleep initiation. Simultaneously, the cortisol-lowering effect reduces the physiological arousal that keeps many people awake — a mechanism that would be particularly relevant for individuals whose sleep difficulties are driven by stress and rumination rather than circadian rhythm disruption.

Testosterone and Exercise: Weaker Claims

Testosterone and exercise performance are the claims most aggressively marketed by ashwagandha supplement brands, and they are also where the evidence is weakest. A 2023 meta-analysis in Phytomedicine (k=4 RCTs, n=318) found a statistically significant but modest testosterone increase of 14.7% in supplemented groups compared to placebo. In absolute terms, this corresponds to an increase of approximately 50–70 ng/dL — meaningful if it moves a hypogonadal individual back into the normal range, but unlikely to produce noticeable effects in a man with already-normal testosterone levels.

Critically, the testosterone increase did not consistently translate to improved body composition or strength gains. A 2022 RCT in Nutrients (n=57, 12 weeks, resistance-trained men) found no significant difference in lean mass accrual, fat mass reduction, or 1-rep max strength between ashwagandha and placebo groups, despite a statistically significant testosterone increase in the ashwagandha group. The testosterone was higher; the practical outcomes were not.

Exercise performance claims (VO2max improvement, faster recovery) are derived from trials with high risk of bias, small sample sizes (n=20–50), and short durations. A 2021 systematic review in the Journal of the International Society of Sports Nutrition concluded that while ashwagandha may improve cardiorespiratory endurance by 3–5%, the quality of evidence is low and the effect sizes are too small to recommend ashwagandha as an ergogenic aid over established interventions (creatine, caffeine, carbohydrate periodization).

Safety Profile: Generally Good, With Important Exceptions

Ashwagandha is generally well-tolerated at 300–600 mg daily for up to 12 weeks in clinical trials. The most common side effects are mild gastrointestinal discomfort (nausea, loose stools) in approximately 5–10% of participants, typically resolving within the first week. Drowsiness is reported occasionally, particularly at higher doses, which is consistent with the GABAergic mechanism and supports taking ashwagandha in the evening rather than the morning for some users.

However, serious safety signals have emerged that warrant careful attention.

Hepatotoxicity. Dr. Victor Navarro, chair of the Drug-Induced Liver Injury (DILI) Network hepatology committee at Einstein Healthcare Network in Philadelphia, reported 16 confirmed cases of liver injury associated with ashwagandha between 2017 and 2023, most involving doses above manufacturer recommendations or concurrent use of other supplements. A 2023 Hepatology review by Dr. Navarro's group identified ashwagandha as the most common herbal cause of drug-induced liver injury in the United States, prompting the United States Pharmacopeia (USP) to add a cautionary label requirement. The absolute risk remains low — 16 cases against millions of users — but it is not zero, and anyone taking ashwagandha should monitor for symptoms of liver injury (jaundice, dark urine, unexplained nausea, upper-right abdominal pain).

Thyroid effects. Ashwagandha may potentiate thyroid hormone levels by 10–15%, as documented by Dr. Ashok Sharma at Jaipur National University (Journal of Alternative and Complementary Medicine, 2018, n=50). A 2022 case series in European Thyroid Journal reported four cases of thyrotoxicosis in individuals taking ashwagandha, three of whom had preexisting subclinical hypothyroidism. This is clinically relevant for anyone with thyroid conditions, taking levothyroxine, or with a family history of thyroid disease. Thyroid function tests (TSH, free T4) should be checked before starting ashwagandha and monitored periodically during use.

Pregnancy. Ashwagandha is contraindicated in pregnancy due to potential abortifacient properties documented in animal studies. No human trials have been conducted in pregnant populations, and the precautionary principle applies.

Drug interactions. Due to its GABAergic and thyroid-potentiating effects, ashwagandha may interact with sedatives, benzodiazepines, thyroid medications, and immunosuppressants. Concurrent use with these medications should be discussed with a healthcare provider.

Ashwagandha vs. Other Adaptogens: How the Evidence Compares

Ashwagandha belongs to a class of botanicals called adaptogens — substances claimed to increase the body's resistance to stress. The term originated in Soviet pharmacology research in the 1960s and encompasses dozens of herbs including rhodiola rosea, holy basil (tulsi), ginseng (Panax ginseng), and eleuthero (Siberian ginseng). The quality of clinical evidence varies dramatically across this category, and understanding where ashwagandha fits helps contextualize its relative strength.

Rhodiola rosea is the closest competitor in evidence quality. A 2012 Phytomedicine systematic review (k=11 RCTs, led by Dr. Sheng-Min Hung at Chung Shan Medical University) found that rhodiola reduced fatigue symptoms and improved cognitive function under stress conditions. The effect sizes were modest but consistent. However, rhodiola's mechanism differs from ashwagandha — it appears to act primarily through modulation of serotonin and dopamine pathways rather than cortisol suppression. For pure stress reduction, ashwagandha has the stronger cortisol data. For mental fatigue and cognitive performance under stress, rhodiola has comparable or slightly stronger evidence.

Panax ginseng has the longest history of clinical investigation, with over 60 RCTs. However, the evidence is fragmented across dozens of indications (cognitive function, erectile dysfunction, blood glucose regulation, immune function) with small effect sizes in most domains. No single indication for ginseng has the concentrated, replicated evidence that ashwagandha has for cortisol reduction and anxiety. Ginseng also has a more significant drug interaction profile, particularly with warfarin and diabetes medications.

The practical takeaway: if your primary goal is stress and anxiety management with established safety data, ashwagandha has the strongest evidence-to-risk ratio in the adaptogen category. If your primary goal is acute cognitive performance under stress (exam preparation, demanding work periods), rhodiola merits consideration. Stacking multiple adaptogens — a common recommendation in supplement marketing — has almost no clinical trial support, and the interaction effects between botanical compounds are poorly understood.

Cycling, Tolerance, and Long-Term Use

A common recommendation in supplement communities is to "cycle" ashwagandha — taking it for 8 to 12 weeks, then discontinuing for 2 to 4 weeks before resuming. The rationale is that the body develops tolerance to the cortisol-modulating effects, reducing efficacy over time. The clinical evidence neither strongly supports nor refutes this practice. The longest published RCT ran for 12 weeks, and no studies have specifically examined whether efficacy diminishes beyond that timeframe or whether cycling restores it.

Dr. K. Chandrasekhar's group did note in follow-up observations that cortisol suppression was maintained at 8 weeks with no evidence of diminishing effect, but the study was not designed to detect long-term tolerance development. In the absence of definitive data, the cycling approach represents a reasonable precautionary strategy — particularly given the theoretical concern that chronic HPA axis suppression could reduce the body's ability to mount an appropriate stress response when needed. A practical approach is 8 to 12 weeks on, 2 to 4 weeks off, reassessing subjective stress and sleep quality during both phases to determine whether the supplement is providing measurable benefit.

Dosing, timing, and practical supplementation guidance

Clinical trials showing positive effects have used ashwagandha root extract (standardized to withanolide content) at doses of 300 to 600 milligrams daily. The two most studied extract forms are KSM-66 (standardized to 5 percent withanolides, typically dosed at 600 mg/day) and Sensoril (standardized to 10 percent withanolides, typically dosed at 125 to 250 mg/day). These are not interchangeable — the different standardizations mean the effective dose differs between products.

Timing: Most clinical trials administered ashwagandha with meals, which improves absorption of the fat-soluble withanolides. For stress and cortisol reduction, splitting the dose (300 mg morning, 300 mg evening) provides more consistent coverage than a single daily dose. For sleep improvement, the full dose taken with the evening meal provides the most consistent benefit in studies measuring sleep quality.

Duration to effect: Most clinical trials showing statistically significant effects ran for 8 to 12 weeks. Subjective stress reduction may appear within 2 to 4 weeks, but cortisol reduction and testosterone effects (in men) typically require 8 weeks of consistent use to reach measurable levels. If no benefit is perceived after 12 weeks, ashwagandha is unlikely to provide meaningful benefit for that individual.

Who should avoid it: Individuals with thyroid disorders (ashwagandha may increase thyroid hormone production), pregnant or breastfeeding women (insufficient safety data), individuals on immunosuppressant medications (ashwagandha has immunomodulatory effects that may interfere with immunosuppression), and individuals on sedative medications (additive sedation risk). Discuss with your prescribing physician before combining ashwagandha with any medication.

Buying Guide: What to Look For

The supplement industry is poorly regulated, and ashwagandha products vary enormously in quality. A 2023 ConsumerLab analysis found that 12% of ashwagandha products contained less than 80% of the labeled withanolide content, and 8% contained lead levels above California Proposition 65 limits — ashwagandha bioaccumulates heavy metals from soil, making sourcing critical.

Choose products with third-party certification from USP, NSF International, or ConsumerLab. Look for a standardized extract (KSM-66 at 5% withanolides, or Sensoril at 10% withanolides) rather than raw root powder. The effective dose is 300–600 mg daily of standardized extract, taken with food. Evaluate efficacy after a minimum of 8 weeks of consistent use — the stress and sleep benefits are not acute; they develop gradually as the HPA axis recalibrates.

The honest summary: credible, replicated evidence for stress and anxiety reduction at 300–600 mg daily. Moderate but growing evidence for sleep quality improvement. Insufficient evidence for testosterone enhancement or exercise performance benefits that would justify supplementation for those purposes alone. A generally favorable safety profile with specific risks (hepatotoxicity, thyroid potentiation) that require awareness and, for some individuals, clinical monitoring.